Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Novo Nordisk's stock plummets over 13% after the company warns of potential sales and profit declines in 2026, facing increasing competition in the weight-loss market, particularly from Eli Lilly's ...